The Eye Institute of Utah | Salt Lake City, UT

Research site

(Unclaimed)

Location

755 East 3900 South, Salt Lake City, Utah, United States of America

Site insights

Top conditions

Top treatments

Riboflavin

SURF-100

Brimonidine

Brimonidine Tartrate

Dexamethasone

PVP

Mycophenolic Acid

riboflavin

Prednisolone

Tavilermide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 24 total trials

Clareon PanOptix Pro vs. Clareon PanOptix - Study A

The purpose of this study is to evaluate the safety and effectiveness of Clareon™ PanOptix™ Pro Trifocal Intraocular Lens (IOL) compared to Clareon™...

Enrolling

Presbyopia

Aphakia

Procedure: Cataract surgery

Device: CPO IOL

Clareon PanOptix Pro vs. Clareon PanOptix - Study B

The purpose of this study is to evaluate the safety and effectiveness of Clareon™ PanOptix™ Pro Trifocal Intraocular Lens (IOL) compared to Clareon™...

Enrolling

Presbyopia

Aphakia

Procedure: Cataract Surgery

Device: CPO Pro IOL

Evaluate the Safety and Effectiveness of ISTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects with Primary Open-angle Glaucoma. (STAR-V)

Evaluate the safety and effectiveness of iSTAR Medical's MINIject™ implant for lowering intraocular pressure (IOP) in subjects with primary open-angl...

Active, not recruiting

Glaucoma

Device: MINIject™ Implant

Hydrus® Microstent New Enrollment Post-Approval Study (CONFIRM)

The purpose of this post-approval study is to evaluate the rate of Hydrus Microstent malposition and associated clinical sequelae occurring within 24...

Enrolling

Primary Open Angle Glaucoma

Device: Hydrus Microstent

Device: Monofocal IOL

Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis (IMAGO)

Primary Objective:To assess the efficacy of cenegermin-bkbj (20 mcg/mL) ophthalmic solution on overall corneal thickness via AS-OCT in patients with...

Active, not recruiting

Neurotrophic Keratopathy

Corneal Ulcer

Drug: OXERVATE® 0.002%

Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix

The purpose of this Post-Market Clinical Follow-up study is to describe the long-term safety and performance of the Clareon Vivity and Vivity Toric a...

Enrolling

Astigmatism

Presbyopia

Device: Clareon PanOptix Trifocal IOL - Toric

Device: Clareon PanOptix Trifocal IOL - Non Toric